| Assessment Status | Rapid Review Complete |
| HTA ID | 22005 |
| Drug | Tofacitinib |
| Brand | Xeljanz® |
| Indication | For the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy. |
| Assessment Process | |
| Rapid review commissioned | 07/02/2022 |
| Rapid review completed | 08/03/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that tofacitinib not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
